This form is to be completed by all investigators who have responded yes to the PHS Financial Interest Screening Questions. Submit this form when requested for pending awards/JIT requests from the Public Health Service (PHS), including the National Institutes of Health (NIH), or any other entity that has adopted the PHS requirements for financial disclosure. This requirement extends to subawards to Indivior.

For more information, <a href="https://grants.nih.gov/grants/policy/coi/index.htm">https://grants.nih.gov/grants/policy/coi/index.htm</a>. For assistance, contact the COI Committee Coordinator (coi\_team@indivior.com).

THIS SUBMITTAL is for a:   New Disclete	osure  Updated Disclosure	
Disclosing Investigator Name:		Email:
Academic Department/Institution:		
Principal Investigator Name (if different fr	om Investigator	Email:
Proposal Number (if New Disclosure):		
Proposal/Project Title:		
Agency Award Number (if Updated Disclo	osure) :	
Proposal Type (please check one):		
☐ Public Health Service (PHS):		(name agency)
Subaward from		under PHS prime
Other (i.e., entity that has adopted PH	S regulations)	
Subaward from	under	prime
	on for which I have already disclosed and been a changes to what I disclosed previously. Please	
	ncial Interests (SFI) of the disclosing Investigator relate omplete a separate Significant Financial Interests – En	
Entity Name	Disclosure Type (Check all that apply.)	Do these interests relate to the above- referenced PHS-funded research project?
Name: Publicly Traded    Non-Publicly Traded    Did you acquire the interest in the past 30 days?    Yes No	☐ Income: \$	Yes No Explanation (required for both yes and no):
Name: Publicly Traded Non-Publicly Traded Did you acquire the interest in the past 30 days? Yes No	☐ Income: \$	☐ Yes ☐ No Explanation (required for both yes and no):
Name: Publicly Traded   Non-Publicly Traded   Did you acquire the interest in the past 30 days?   Yes   No	☐ Income: \$ ☐ IP (including royalties, license fees, etc.) ☐ Stock and/or Stock Options Number of Shares: Estimated Current Stock Value: \$ % of Issued and Outstanding Shares: ☐ <5% ☐ 6-10% ☐ 11-25% ☐ >26%	☐ Yes ☐ No Explanation (required for both yes and no):

Disclosure (cont	tinued)				
Entity Name  Name: Publicly Traded Non-Publicly Traded Did you acquire the interest in the past 30 days? Yes No		Disclosure Type (Check all that apply.)  Income: \$ IP (including royalties, license fees, etc.)  Stock and/or Stock Options Number of Shares: Estimated Current Stock Value: \$ % of Issued and Outstanding Shares:    <5%   6-10%   11-25%   >26%			Do these interests relate to the above- referenced PHS-funded research project?
					Yes No Explanation (required for both yes and no):
Name:  Publicly Traded Non-Publicly Traded Did you acquire the interest in the past 30 days?  Yes No		☐ Income: \$		_	☐ Yes ☐ No Explanation (required for both yes and no):
an Institution of higher ed Institution of higher educ Report any reimbursed o coi_team@Indivior.com	ess of \$5,000 per entir ducation as defined by ation. <i>Attach addition</i> or sponsored travel in e	avel  ty. Exclude travel the 20 U.S.C. 1001(a), all sheets as necessors \$5,000 periods.	an academic teaching hosp sary.  r entity not included below	ored by a pital, a m	U.S. federal, state, or local government agency, nedical center, or a research institute affiliated with 30 days after the travel occurs by sending email to
Recent Travel (last 1 Entity	Destination		entity) uration	Purp	pose of Trip
Planned Travel (upcoming 12 months)					
Entity	Destination  Continenta Other		uration ] 1-5 Days  ☐ 6-10 Days ] Over 10 Days		pose of Trip
	☐ Continenta	IU.S.	] 1-5 Days		
	☐ Continenta	IU.S.	]1-5 Days ☐ 6-10 Days ]Over 10 Days		
	Continenta Other	IU.S.	] 1-5 Days		
	Continenta	ı u.s.   [	] 1-5 Days		

### **Significant Financial Interests - Entity**

**Important:** Complete the following pages **for each entity** with which you have a Significant Financial Interests (SFI) (see Disclosure section), and attach to form. For convenience for multiple entities, this section is available as a separate PHS Financial Disclosure: Significant Financial Interests - Entity.

N	Name of Entity:	Entity's Address:
1	Name of Enuty.	Entity's Address.
F	Principal Business of Entity:	
	·	
SI	FI - Income	
1.	If you received any consulting income from the Entity, please specif	
ſ	(If consulting income exceeded \$5,000 within the last 12 months, ple	ease attach a copy of the consulting agreement.)
_ [ _		
2. 「	If you received other income or payment for services from the Entity	r, please describe the services for which payment was received.
Į		
R	elationship with Entity	
lm	pact on Financial Interests	
3.		of any drugs or devices or the development of a product or service of interest to
	the entity?	
ſ	☐ No ☐ Yes - if yes, please explain:	
Į		
4.	Does, or will, the Entity manufacture or commercialize any device, p predictably result from the PHS-funded research project listed above	procedure, drug, vaccine or any other product that is associated with or that will
	☐ No ☐ Yes - if yes, please explain:	o:
ſ		
ا 5	Is it reasonable to anticipate that the Entity could be affected by the	PHS-funded research project listed above? Affected may include, but is not
Ο.	limited to, business impact if licensing interest in research results.	The funded research project listed above: Allected may include, but is not
	☐ No - if no, please explain:	
	Yes - if yes, please explain:	
6.	If you, your spouse, registered domestic partner, or dependent child	I(ren) hold a position of management with the Entity, state the position title,
_	describe the responsibilities of the position, and explain any relation	

_				
₹e	elationship with Entity (contir	nued)		
<b>.</b>		a subcontractor, consortium member, supplie	er of good	s, lessor or other involvement in the project, explain and
Г	describe.			
L				
<u> </u>	paration of Indivior and Outside	Interests		
3. 		obligations to the Entity separate from your a d include examples of a clear division of the		ssociated with the PHS-funded research pals and business interests and the aims of the PHS-
).	Are there any mitigating factors? (Che	eck all that apply.)		
_	Entity is one of at least several involve	· · · · · · · · · · · · · · · · · · ·		pany with products unrelated to this research
Ц	Other non-conflicted Investigators coll	ect data and perform data analyses	None of the	e above
		wing for use in the PHS-funded research proj	ect listed	<u> </u>
_	Proprietary data	☐ Test material, research tools or drugs		☐ Equipment or devices
_	Entity's facility	Entity's personnel		None
— Or	penness of Teaching and Res	search Environment		
•	•	te or postdoctoral students involved in the Ph	-IS-funded	research project listed above?
•	☐ No - if no, skip to question 1		io idildod	riododi ori project noted above.
	Yes - if yes, please explain:			
2.	Are you the advisor to any of these st	udents?		
	☐ No			
	Yes			
3.	Are there any constraints or restriction	ns imposed on the reporting of student work?	•	
	☐ No			
	Yes - if yes, please explain:			
L				
i	censing			
	•	ild/ron) have an inventive or authorship inter-	act in any	intellectual property that will be utilized in the PHS-
4.	funded research project listed above?	ind(ren) have an inventive of ownership inter-	est iii ariy	intellectual property that will be utilized in the Pho-
	☐ No - if no, skip to question 1	6.		
	Yes - if yes, provide a brief	non-technical description of the intellectual p	roperty inv	volved:
Γ				
L				

Licens	sing (continued)
15.	Please identify the owner of the intellectual property to be utilized in the project:
	Self
	Other (identify):
	s the Entity hold rights to a pending application or issued patent to an invention, license right, or copyright for software of yours, your spouse or
dep	endent child(ren)?
	□ No
	Yes: the license is from Indivior  Yes: the application, patent, license or copyright does not involve Indivior-owned intellectual property
47 DI	
17. Plea	ase list any previous and pending patents and any recently submitted disclosure of inventions of yours.
Compl to forn	ete the above Significant Financial Interests - Entity section for each entity listed in the Disclosure section and attach n.
Certi	fication by Disclosing Investigator
responitis true	under penalty of perjury that this is a complete disclosure of all my significant financial interests related to my institutional sibilities and I have used all reasonable diligence in preparing this Financial Interest Disclosure, and to the best of my knowledge and complete. I also acknowledge that by signing my name below that it is my responsibility to disclose, within 30 days, any gnificant financial interests obtained during the term of the above proposed project.
Signati	ure: Date:
J	